Gracell Biotechnologies Company
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Technology:
CAR-T, CAR-T therapy
Industry:
CAR-T, Public
Headquarters:
Suzhou, Jiangsu, China
Founded Date:
2017-01-01
Employees Number:
51-100
Funding Status:
IPO
Investors Number:
10
Total Funding:
185000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2020-10-28
Last Funding Type:
Series C
Register and Claim Ownership